Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
about
The origin and role of innate lymphoid cells in the lungMaintenance of Immune Homeostasis through ILC/T Cell InteractionsIntrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatmentsRegulation of the adaptive immune system by innate lymphoid cellsDaclizumab therapy for multiple sclerosisReview of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosisTherapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisTertiary Lymphoid Organs in Central Nervous System AutoimmunityThe effects of interleukin-2 on immune response regulation.The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.How implementation of systems biology into clinical trials accelerates understanding of diseases.Establishment and function of tissue-resident innate lymphoid cells in the skin.A complex role of herpes viruses in the disease process of multiple sclerosis.Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential.CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MSThe meninges: new therapeutic targets for multiple sclerosis.Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosisInnate lymphoid cells. Innate lymphoid cells: a new paradigm in immunologyRORγt Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis.The single nucleotide variant rs12722489 determines differential estrogen receptor binding and enhancer properties of an IL2RA intronic regionInnate lymphoid cell interactions with microbiota: implications for intestinal health and disease.Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes.Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccinationCutaneous adverse events in multiple sclerosis patients treated with daclizumabThe effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.Expansion of inflammatory innate lymphoid cells in patients with common variable immune deficiencyInnate lymphoid cells in the initiation, regulation and resolution of inflammationImpaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulationAlemtuzumab treatment alters circulating innate immune cells in multiple sclerosis.Emerging concepts and future challenges in innate lymphoid cell biologyEffect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.Teriflunomide and its mechanism of action in multiple sclerosis.The role of natural killer cells in multiple sclerosis and their therapeutic implications.Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The CD25-binding antibody Daclizumab High-Yield Process has a distinct glycosylation pattern and reduced antibody-dependent cell-mediated cytotoxicity in comparison to Zenapax®.CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.Daclizumab for the treatment of multiple sclerosis.
P2860
Q26740079-0230304B-A69B-4A74-BDEB-C22C345A8012Q26796071-8C17BF6A-BCD7-4824-A607-7FB582D6037CQ26851694-67ABEF61-76E1-48B9-998C-036F0D7D6B3FQ26864694-A9BFE490-E45D-4FC0-AFA7-128F6C8F36A3Q27022517-D717058E-E70B-448B-8F77-7D98A056D427Q27693249-E7A0FD12-0FB6-49C3-AEA3-CAED560B34E7Q28066677-A5DAF976-4CE1-475D-A415-F614ACCEC41BQ28071379-F64B1D11-961F-4593-8F7A-4127BA0AA36AQ30252875-0661C64B-66D9-49CB-9902-02080C25E506Q30730505-622A4C76-F231-44E2-A0FE-092BCB6266EEQ33814843-71D4E43C-0EF2-4574-BAAA-564A8569E63AQ33874975-B883BC23-12DC-49FF-9BBE-2EDCDD110C1AQ34078589-E0623272-05D0-4B59-8F06-1AC710E3F0DFQ34504952-8C428000-CBB1-4A58-8A1E-7DD4831D2C42Q34550631-6B4127E0-2117-4CEE-9D62-ABB0CD631DE4Q35023350-C28E7F5A-A702-4D83-9EBE-8B99EDA2EBC9Q35584727-0ECEE55C-EB62-4262-8895-69408470B45DQ35619174-1A34C2C3-B8F3-4282-945D-9631FF933748Q35638915-ADC846DA-DE55-41C1-ADE3-972A0D4E8B2DQ36076923-59580BC9-C8E0-43B7-B4A5-E05E09EFD071Q36289774-0F9E6FB7-8EC4-45C9-A5F7-9814F2BC235FQ36390314-EC6A5C83-D0F7-4592-A5FB-409DBFBF5F45Q36410286-A7F7E160-38B9-4346-ACEC-94C2C0494893Q36521247-791259C4-8F0D-4261-B83E-81CB3DF0BC09Q36691970-27BB0E0D-5B07-45EC-BC77-730AADA3068FQ36748094-9F7B135F-6D95-4405-9B33-D5A6985384B5Q36900160-16B2685B-9EDC-433C-86DA-E9541D182884Q36908615-7FD985CF-9A97-4CFF-B9BA-3789D157FE0AQ36957280-96F08BB2-E808-4186-A8C1-44881B3F66A7Q37337775-796A5F6E-80D6-496E-8A6A-88BD306F92A2Q37346684-558E987F-59E4-474F-A26B-C53CB5A33E26Q37558843-EAB81B23-90AF-4BE2-8043-CCF9D3BD1FD7Q37657070-820DC835-998A-420F-AB11-65B7A6B19AFCQ37730005-36B8BD6D-97FB-465D-A973-88E7DA567F61Q38089599-F96EBF34-29C7-4E44-877A-8D61BC1ED7D9Q38111620-B1E2E86A-3BF6-4D37-BD73-4E3E695EBA90Q38172961-75C12DC9-1782-4A7C-86C6-AB9F10D1E574Q38291845-C8F5EAEF-7DD6-4DD5-95BB-4E1EC5B83484Q38577294-C6EEB649-21C4-4C00-AD68-48B8C15EF836Q38604207-489775F2-1C72-4FD8-8FC2-AF8AA6033977
P2860
Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@en
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@nl
type
label
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@en
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@nl
prefLabel
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@en
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@nl
P2093
P2860
P1476
Inhibition of LTi cell develop ...... mmation in multiple sclerosis.
@en
P2093
Bibiana Bielekova
Gyorgy Csako
Justin S A Perry
Lucy B Kennedy
Matthew L Herman
Quangang Xu
Sungpil Han
P2860
P304
P356
10.1126/SCITRANSLMED.3004140
P407
P577
2012-08-01T00:00:00Z